Kunena :: Тема: Posted by Emerald Mcmanuson 28.11.2016 16:54:03: how well does tarceva work (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Emerald Mcmanuson 28.11.2016 16:54:03: how well does tarceva work

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Emerald Mcmanuson 28.11.2016 16:54:03: how well does tarceva work

Страница:
1
2

ТЕМА: Posted by Emerald Mcmanuson 28.11.2016 16:54:03: how well does tarceva work

Posted by Emerald Mcmanuson 28.11.2016 16:54:03: how well does tarceva work 7 года 5 мес. назад #895

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
And Dr. West has written a post on the use of Tarceva by elderly patients: cancergrace.org/lung/2008/06/21/tarceva-in-elderly/
The lawsuit specifically alleged that between January 2006 and December 2011, Genentech and OSI Pharmaceuticals made misleading representations to physicians and other health care providers about the effectiveness of Tarceva to treat certain patients with non-small cell lung cancer, when there was little evidence to show that Tarceva was effective to treat those patients unless they also had never smoked or had a mutation in their epidermal growth factor receptor, which is a protein involved in the growth and spread of cancer cells.
Time on Tarceva when people have Joint Aches *:
ihearyou.ru/index.php/kunena/razdel-pred...ceva-cured-my-cancer
10 10/33 Ved lungekreft betyr prognostiske faktorer og sykdomsutbredelse ved diagnose mer for prognosen enn behandlingen som pasienten får. Dårlige prognostiske faktorer: WHO/ECOG-status 2 Største tumordiameter < 9 cm Vekttap > 5 10 % de siste 3 måneder Ikke- småcellet lungekreft anses om en alvorlig sykdom, og oppfyller etter Legemiddelverkets vurdering kriterium a) og b) i Legemiddelforskriftens om alvorlig sykdom og krav om langvarig behandling for innvilgelse av forhåndsgodkjent refusjon. 1.2 Behandling av ikke-småcellet lungekreft Det finnes tre aktuelle behandlingsmetoder ved lungekreft kirurgi, kjemoterapi og strålebehandling. Disse gis enten alene eller i ulike kombinasjoner. Det som avgjør valg av behandlingsform er sykdomsutbredelse (stadium), vevstype (småcellet eller ikke-småcellet) og pasientens allmenntilstand eller annen samtidig sykdom. For pasienter med lokalavansert eller metastatisk NSCLC er operasjon som regel ikke mulig å gjennomføre på grunn av svulstens beliggenhet. Ved gode prognostiske faktorer legges det opp til kurativ strålebehandling, eventuelt i kombinasjon med cytostatika. Ved dårlige prognostiske faktorer tilbys pasienten palliativ behandling, i form av strålebehandling eller cytostatika. Ved metastatisk sykdom (stadium IV) vil pasienten tilbys palliativ behandling med stråleterapi eller kjemoterapi. Platinumbasert kjemoterapi har hittil blitt brukt som førstevalg ved utbredt sykdom. En rekke palliative regimer vil være aktuelle, og er effektmessig likeverdige. Bivirkningsprofil er som regel det eneste som skiller. Ved progresjon på førstelinje behandling kan monoterapi docetaxel, eventuelt pemetrexed, forsøkes. Erlotinib er godkjent som andrelinjebehandling ved metastatisk ikkesmåcellet lungekreft [2] [3] I følge klinisk ekspertise ved Oslo Universitetssykehus, Radiumhospitalet, er anbefalingen for pasienter med NSCLC det følgende: Førstelinjebehandling: dobbel kjemoterapi med carboplatin og vinorelbin, tre- fire kurer med 3 ukers intervall. Hos pasienter som ikke tolererer kjemoterapi og er EGFRmutasjonspositive, er gefitinib anbefalt i førstelinje frem til progresjon. I andre linje etter konvensjonell kjemoterapi hos pasienter som er EGFRmutasjonspositive er erlotinib (Tarceva) eller gefitinib anbefalt.
Erlotinib or gefitinib as first-line treatment for unselected chemonaïve advanced NSCLC in phase II trials
radio26.ru/index.php/kunena-2013-10-03/r...-52-egfr-and-tarceva
NOTE. OSI-420 is the main metabolite of erlotinib.
We are the prominent organization, indulged in offering a wide range of Erlotinib Tablets. Offered Erlonat medicines are processed by top quality ingredients in compliance with the set medical norms. These Erlonatmore..
En los ensayos iniciales de fase I de erlotinib se evalúan diferentes dosis y diferentes regímenes hasta encontrar la dosis máxima tolerada (150 mg) 6 . En los resultados del estudio BR.21 3 , las tasas de respuesta fueron superiores en los siguientes grupos de pacientes: mujeres, no fumadores, etnia asiática y aquellos con histología de adenocarcinoma. Diarrea y exantema fueron las reacciones adversas más frecuentes en este estudio. En contraposición con este estudio anterior, en un estudio europeo (TRUST, fase IV) 7 se observa un beneficio de menor calibre en los pacientes que supuestamente iban a tener un peor pronóstico. Las toxicidades más frecuentes sí coinciden con las del estudio BR.21 (diarrea y exantema). Emery et al. 8 llevaron a cabo un estudio retrospectivo con 160 pacientes con CPNM. Recibieron gefinitib 115 pacientes y 45 erlotinib, siendo este último ligeramente superior en todas las medidas de respuesta, aunque no fue estadísticamente significativo. Los efectos adversos más comunes fueron, en ambos grupos: exantema, diarrea, náuseas, vómitos y fatiga. En la guía del National Institute for Health and Clinical Excellence (NICE) para el tratamiento con erlotinib del cáncer de pulmón no microcítico 9 se recogen los siguientes efectos secundarios: diarrea, erupción, anorexia, hemorragia gastrointestinal, alteraciones de la función hepática y queratitis.
www.learninvest.ru/index.php/kunena/dobr...lotinib-egfr-pathway
TARCEVA 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULA.
Comme l'Erlotinib, il est métabolisé par le cytochrome P450 3A4 . de ce fait, il est recommandé aux patients de ne pas boire du jus de pamplemousse en même temps.
kaprfnso.ru/index.php/kunena/problemy-go...warfarin-interaction
Comment: I have been taking Tarceva 150 mg for almost 5 years now and still on remission the only side effects I have is skin rash that can be painful and diarrhea,otherwise my hair gets thicker ang grow eyelashes Hide Full Comment
Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353. 133. 2005 -144, Medline
Non-Small Cell Lung Cancer: EGFR gene amplification and/or high polysomy, as measured by FISH testing, are associated with a favorable clinical benefit in patients with non-small cell lung carcinoma (NSCLC) who are treated with tyrosine kinase inhibitors (TKI), such as gefitinib and erlotinib.
E7820 (50) + erlotinib (60)
If you are unsure about anything related to dosing with erlotinib, please talk with your healthcare provider, nurse, or pharmacist.
The 13-gene signature was used to develop a predictive algorithm of response to erlotinib utilising our previously published DLDA ( Balko et al . 2006 ). A leave-one-out cross-validation assay was used to internally validate the predictor using training cell line data (resistant lines = A549, H460, H1975, and UKY29; sensitive lines = H1650, H3255, H358, and PC9). H1975 cells failed this validation. H1975 cells are genetically different compared with the other resistant lines in that they contain an EGFR mutation correlating with sensitivity and a second mutation that confers resistance ( Gendreau et al . 2007 ; Figure 1A ).
dnz2.rosvita.rv.ua/index.php/forum/skrin...ous-cell-lung-cancer
Product Code. Erlonat 150 mg
Lung Diseases Respiratory Tract Diseases Erlotinib Hydrochloride Cetuximab Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
Establishment of erlotinib-resistant non-small cell lung cancer A549 cells
Drug: Sunitinib Drug: Erlotinib Drug: Midazolam Drug: Caffeine
OSI Pharmaceuticals and Genentech Provide Update on Status of Tarceva Program
forwardnsk.ru/index.php/forum/razlichnye...35-erlotinib-tarceva
Product details for Tarceva
Other: Erlotinib plus hypofractionated radiotherapy
If patients are tolerating it, I have them continue tarceva until we repeat a scan, usually after about two months, and then decide whether to continue it or not.
Co-administration of erlotinib with the potent CYP3A4 inhibitor, ketoconazole, resulted in a clinically relevant increase in erlotinib exposure. Rifampicin, a potent CYP3A4 inducer, co-administered with erlotinib significantly decreased erlotinib exposure. Cautionary statements have been incorporated in the Product Monograph. The sponsor is performing additional studies to assess dose adjustments for the co-administration with rifampicin, and to determine the effect of erlotinib on the pharmacokinetics of the CYP3A4 substrate, midazolam.
www.antei-cdl.ru/index.php?option=com_ku...w&catid=4&id=327#327
Is Erlonat Tablet safe while breastfeeding?